Article
Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.
CNS neuroscience & therapeutics - 1 Apr 2024
Liang Bao-Bao, Wang Yu-Hong, Huang Jing-Jing, Lin Shuai, Mao Guo-Chao, Zhou Zhang-Jian, Yan Wan-Jun, Shan Chang-You, Wu Hui-Zi, Etcheverry Amandine, He Ya-Long, Liu Fang-Fang, Kang Hua-Feng, Yin An-An, Zhang Shu-Qun
Abstract excerpt
PURPOSES: To identify potent DNA methylation candidates that could predict response to temozolomide (TMZ) in glioblastomas (GBMs) that do not have glioma-CpGs island methylator phenotype (G-CIMP) but have an unmethylated promoter of O-6-methylguanine-DNA methyltransferase (unMGMT). METHODS: The discovery-validation approach was planned incorporating a series of G-CIMP-/unMGMT GBM cohorts with DNA methylation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.